MCID: PRT018
MIFTS: 52

Portal Vein Thrombosis

Categories: Blood diseases, Cardiovascular diseases, Gastrointestinal diseases, Liver diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Portal Vein Thrombosis

MalaCards integrated aliases for Portal Vein Thrombosis:

Name: Portal Vein Thrombosis 11 75 28 53 14 71 31 33
Deep Vein Thrombosis of Portal Vein 33
Occlusion of Hepatic Portal Vein 33
Hepatic Portal Vein Obstruction 33
Pvt - [portal Vein Thrombosis] 33
Portal Venous Obstruction 33
Phlebitis of Portal Vein 33
Portal Venous Thrombosis 33
Portal Vein Obstruction 33
Portal Venous Embolism 33
Portal Vein Embolism 33
Portal Venous Block 33
Portal Obstruction 33
Portal Thrombosis 33
Portal Vein Block 33
Portal Embolism 33
Portal Block 33

Classifications:



External Ids:

Disease Ontology 11 DOID:11695
ICD9CM 34 452
NCIt 49 C78565
SNOMED-CT 68 155455003
ICD10 31 I81
ICD11 33 866276949
UMLS 71 C0155773

Summaries for Portal Vein Thrombosis

Disease Ontology: 11 A hepatic vascular disease that is characterized by a blood clot that forms within the hepatic portal vein.

MalaCards based summary: Portal Vein Thrombosis, also known as deep vein thrombosis of portal vein, is related to hepatic encephalopathy and liver cirrhosis. An important gene associated with Portal Vein Thrombosis is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Heparin, bovine and Ethiodized oil have been mentioned in the context of this disorder. Affiliated tissues include liver, neutrophil and endothelial, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia: 75 Portal vein thrombosis (PVT) is a vascular disease of the liver that occurs when a blood clot occurs in... more...

Related Diseases for Portal Vein Thrombosis

Diseases related to Portal Vein Thrombosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 809)
# Related Disease Score Top Affiliating Genes
1 hepatic encephalopathy 31.5 GPT F2 ALB
2 liver cirrhosis 31.5 THPO SERPINC1 GPT F3 F2 ALB
3 portal hypertension 31.4 THPO PIGM JAK2 GPT F2 ALB
4 varicose veins 31.3 VWF THBD SERPINC1 MTHFR F5 F2
5 vitamin k deficiency bleeding 31.1 SERPINC1 F8 F3 F2 AFP
6 alcoholic liver cirrhosis 31.0 GPT F2 ALB AFP
7 biliary atresia 31.0 GPT F2 ALB
8 non-alcoholic steatohepatitis 31.0 GPT ALB AFP
9 liver disease 31.0 THPO GPT F3 F2 ALB AFP
10 cholecystitis 30.9 GPT F2 CRP ALB
11 homocysteinemia 30.9 MTHFR F5 F2
12 hemophilia 30.8 VWF F8 F2
13 cavernous hemangioma 30.8 VWF SERPINC1 F3 F2 ALB AFP
14 autoimmune hepatitis 30.8 GPT F2 CD40LG ALB
15 hepatitis b 30.7 GPT F2 ALB AFP
16 cholangitis 30.7 GPT F3 F2 CRP ALB
17 protein c deficiency 30.7 THBD SERPINC1 MTHFR F5 F2 APOH
18 factor vii deficiency 30.7 SERPINC1 F8 F3 F2
19 hypersplenism 30.7 THPO SERPINC1 GPT F3 F2 ALB
20 hepatorenal syndrome 30.6 GPT F2 ALB AFP
21 factor viii deficiency 30.6 VWF SERPINC1 F8 F5 F3 F2
22 klatskin's tumor 30.6 GPT F2 ALB AFP
23 esophageal varix 30.6 THPO SERPINC1 GPT F3 F2 CRP
24 protein s deficiency 30.5 THBD SERPINC1 MTHFR F5 F3 F2
25 obstructive jaundice 30.5 GPT F2 CRP ALB AFP
26 acute kidney failure 30.5 GPT F2 ALB
27 primary biliary cholangitis 30.4 GPT F2 CD40LG ALB AFP
28 pregnancy loss, recurrent 1 30.4 MTHFR F5 APOH
29 choledocholithiasis 30.4 GPT F2 CRP ALB
30 covid-19 30.4 PLG F3 F2 CRP
31 acute vascular insufficiency of intestine 30.4 SERPINC1 CRP ALB
32 wilson disease 30.4 GPT F2 ALB
33 schistosomiasis 30.4 GPT F2 CRP CD40LG ALB
34 hepatic tuberculosis 30.4 GPT F2 ALB AFP
35 hemophilia a 30.4 VWF F8 F5 F3 F2
36 lymph node tuberculosis 30.3 CRP ALB
37 polyarteritis nodosa 30.3 GPT CRP APOH
38 alcohol use disorder 30.3 GPT F2 CRP ALB AFP
39 severe acute respiratory syndrome 30.3 GPT F3 CRP
40 thrombocythemia 1 30.3 THPO MPL
41 protein-losing enteropathy 30.3 SERPINC1 GPT F2 CRP ALB
42 abdominal tuberculosis 30.2 GPT F2 CRP ALB AFP
43 cholelithiasis 30.2 GPT CRP ALB
44 heparin-induced thrombocytopenia 30.2 PF4 F3 F2
45 diarrhea 30.2 VWF GPT CD40LG ALB
46 bowel dysfunction 30.2 GPT CRP ALB
47 dengue disease 30.2 GPT CD40LG ALB
48 hepatic infarction 30.2 SERPINC1 GPT F3 F2 APOH ALB
49 nephrotic syndrome 30.2 SERPINC1 PLG F3 F2 CRP ALB
50 sclerosing cholangitis 30.1 GPT F2 CRP ALB AFP

Comorbidity relations with Portal Vein Thrombosis via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Vascular Insufficiency of Intestine
Hepatic Encephalopathy Portal Hypertension

Graphical network of the top 20 diseases related to Portal Vein Thrombosis:



Diseases related to Portal Vein Thrombosis

Symptoms & Phenotypes for Portal Vein Thrombosis

GenomeRNAi Phenotypes related to Portal Vein Thrombosis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 AFP ALB APOH CD40LG CRP F2
2 no effect GR00402-S-2 10.18 ALB APOH CD40LG CRP F2 F3

MGI Mouse Phenotypes related to Portal Vein Thrombosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.28 AFP ALB APOH CD40LG CRP F2
2 cardiovascular system MP:0005385 10 ALB CD40LG CRP F2 F3 F5
3 liver/biliary system MP:0005370 9.97 AFP ALB F5 JAK2 MTHFR PLG
4 immune system MP:0005387 9.97 ALB CD40LG CRP F2 F3 F8
5 hematopoietic system MP:0005397 9.73 CD40LG F2 F3 F8 JAK2 MPL
6 mortality/aging MP:0010768 9.5 ALB APOH CD40LG F2 F3 F5

Drugs & Therapeutics for Portal Vein Thrombosis

Drugs for Portal Vein Thrombosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
2
Ethiodized oil Approved, Investigational Phase 4 8008-53-5
3
Cisplatin Approved Phase 4 15663-27-1 2767 5702198 441203
4
Warfarin Approved Phase 4 81-81-2, 129-06-6 54678486
5
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
6
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
7
Nadroparin Approved, Investigational Phase 4
8
Apixaban Approved Phase 4 503612-47-3 10182969
9
Reviparin Approved, Investigational Phase 4 9041-08-1
10
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
11
Dipyridamole Approved Phase 4 58-32-2 3108
12 Fibrinolytic Agents Phase 4
13 Anticoagulants Phase 4
14 Calcium heparin Phase 4
15 Pharmaceutical Solutions Phase 4
16 Gelatin Sponge, Absorbable Phase 4
17 Calcium, Dietary Phase 4
18 Factor Xa Inhibitors Phase 4
19 HIV Protease Inhibitors Phase 4
20 Serine Proteinase Inhibitors Phase 4
21 Antithrombins Phase 4
22 Antithrombin III Phase 4
23 Heparin, Low-Molecular-Weight Phase 4
24
protease inhibitors Phase 4
25 Liver Extracts Phase 4
26 Vasodilator Agents Phase 4
27 Analgesics Phase 4
28 Antirheumatic Agents Phase 4
29 Antipyretics Phase 4
30 Phosphodiesterase Inhibitors Phase 4
31 Cyclooxygenase Inhibitors Phase 4
32 Platelet Aggregation Inhibitors Phase 4
33 Anti-Inflammatory Agents, Non-Steroidal Phase 4
34 Analgesics, Non-Narcotic Phase 4
35 Anti-Inflammatory Agents Phase 4
36
Calcium Nutraceutical Phase 4 7440-70-2 271
37
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
38
Rivaroxaban Approved Phase 3 366789-02-8 9875401
39
Propranolol Approved, Investigational Phase 3 318-98-9, 525-66-6 62882 4946
40
Simvastatin Approved Phase 3 79902-63-9 54454
41
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239
42 Neurotransmitter Agents Phase 3
43 Adrenergic Antagonists Phase 3
44 Adrenergic Agents Phase 3
45 Antihypertensive Agents Phase 3
46 Anti-Arrhythmia Agents Phase 3
47 Antimetabolites Phase 3
48 Hypolipidemic Agents Phase 3
49 Anticholesteremic Agents Phase 3
50 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 61)
# Name Status NCT ID Phase Drugs
1 Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis:A Zelen-design Multicenter Randomized Controlled Trial Unknown status NCT02630095 Phase 4 Nadroparin Calcium and Warfarin
2 A Zelen-design Randomized Controlled Trial of the Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Unknown status NCT02398357 Phase 4 Nadroparin Calcium and Warfarin
3 Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Unknown status NCT02238444 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
4 Efficacy and Safety of Nadroparin Calcium-Warfarin Sequential Anticoagulation in Portal Vein Thrombosis in Cirrhotic Patients:A Randomized Controlled Trial Completed NCT04173429 Phase 4 Nadroparin calcium, warfarin
5 Initiation of NWS Anticoagulation Therapy After Oesophageal Variceal Band Ligation Was Safe in Portal Vein Thrombosis Patients With Cirrhosis and Acute Variceal Bleeding: A Multi-central Randomized Controlled Trial Completed NCT04976543 Phase 4 nadroparin calcium-warfarin sequential anticoagulation
6 Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy and Azygoportal Disconnection for Portal Hypertension Completed NCT02247414 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
7 Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis Completed NCT03007212 Phase 4
8 Efficacy and Safety of Apixaban, Warfarin and Aspirin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy Recruiting NCT04645550 Phase 4 Apixaban;Warfarin;Aspirin;Dipyridamole;Low molecular weight heparin
9 Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study Unknown status NCT02627053 Phase 3 rivaroxaban
10 Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic Portal Vein Thrombosis in HCV Related Compensated Cirrhosis Unknown status NCT03193502 Phase 3 rivaroxaban
11 Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis (PVT) and Cavernous Transformation of the Portal Vein (CTPV) Unknown status NCT02853526 Phase 3 Propranolol;Warfarin
12 Minimal Hepatic Encephalopathy in Pre-hepatic Portal Hypertension Due to Portal Vein Thrombosis in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study. Unknown status NCT01798329 Phase 3
13 A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism Completed NCT02585713 Phase 3 Apixaban;Dalteparin
14 Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis Completed NCT02250391 Phase 3 NPB-06;Placebo
15 Multicentric Randomized Study of Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. Completed NCT02555111 Phase 3 Xarelto
16 A Randomized, Multicenter,Double Blind,Controlled With Placebo Trial About Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Liver Cirrhosis and Variceal Bleeding Completed NCT01095185 Phase 3 Simvastatin;Placebo
17 SBRT Sequential TACE Combined With Sorafenib Versus Sorafenib Alone in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus:A Single-center Randomized Controlled Study Recruiting NCT04387695 Phase 3 Sorafenib
18 A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT) Terminated NCT01887717 Phase 3 Sorafenib
19 An Investigator-initiated, Multicentre, Randomized, Trial Comparing Anticoagulation Alone Versus Transjugular Intrahepatic Portosystemic Shunt (TIPS) and Anticoagulation in Patients With Recent Obstructive Portal Vein Thrombosis Withdrawn NCT03422419 Phase 3 Heparin
20 Randomized Trial of Sorafenib Plus Hepatic Arterial Infusion With Oxaliplatin and Fluorouracil Versus Sorafenib for Hepatocellular Carcinoma With Major Portal Vein Tumor Thrombosis Completed NCT03009461 Phase 2 Sorafenib
21 Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion: PORTAL Study Recruiting NCT05625893 Phase 2
22 Hepatic Arterial Infusion Chemotherapy Combine With Lenvatinib and Camrelizumab for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. Recruiting NCT05166239 Phase 2 Lenvatinib 1;Camrelizumab 1;Lenvatinib 2;Camrelizumab 2
23 A Randomized, Double-blinded, Controlled Phase II Study of Combination Therapy of HAIC (Hepatic Arterial Infusion Chemotherapy), HLX10 (PD-1 Antibody) and HLX04 (VEGF Antibody) Compared With HAIC and Placebo in Hepatocellular Carcinoma With Major Portal Vein Tumor Thrombosis Not yet recruiting NCT04947826 Phase 2 HLX10 (PD-1 antibody);HLX04 (VEGF antibody);Placebo
24 Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With Stereotactic Body Radiotherapy for Hepatocellular Carcinoma Patients With Portal Vein Thrombosis. Not yet recruiting NCT05286320 Phase 1, Phase 2 Lenvatinib/Pembrolizumab plus SBRT combinations
25 Effect of Anticoagulation in Reducing the Incidence of Splenic/Portal Vein Thrombosis Post-Laparoscopic Splenectomy Protocol Number: 5698 Terminated NCT00769873 Phase 2 Enoxaparin
26 Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis: A Randomized, Double-blinded, Placebo - Controlled Trial (PiVoT-AC Trial) Withdrawn NCT04055389 Phase 1 Antithrombin III
27 Role of Endoscopic Ultrasound Guided Fine Needle Aspiration of Portal Vein Thrombus in the Diagnosis and Staging of Hepatocellular Carcinoma Unknown status NCT03902678
28 Comparison in Portal Flow After Sleeve Gastrectomy and Mini Gastric Bypass Unknown status NCT02733770
29 The Effect of Rifaximin on Portal Vein Thrombosis in Cirrhotic Patients Unknown status NCT03631147 Rifaximin
30 Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) or Portal Vein Thrombosis Unknown status NCT02309788
31 STUDY OF THE ADAMTS-13 LEVEL AS PREDICTIVE BIOMARKER FOR DEVELOPMENT OF PORTAL VEIN THROMBOSIS IN LIVER CIRRHOSIS Unknown status NCT03322696
32 Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy in a High-volume Center. A Cohort Study. Unknown status NCT02597218
33 A Practical Nomogram Based on Systemic Inflammatory Markers for Predicting Portal Vein Thrombosis in Patients With Liver Cirrhosis Completed NCT05541562
34 Prevalence and Predictive Factors of Portal Vein Thrombosis in Patients With Cirrhosis Completed NCT02069457
35 Outcomes of Surgical Strategies for Living Donor Liver Transplantation to Patients With Portal Vein Thrombosis Completed NCT05132192
36 Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic Portal Vein Thrombosis in HCV Related Compensated Cirrhosis Completed NCT03201367 Rivaroxaban
37 EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications Completed NCT03477149
38 Analysis of Neutrophil Extracellular Traps in Hypercoagulability and Portal Vein Thrombosis in Liver Cirrhosis Patients Completed NCT05012501
39 Risk Factors for Recurrence of Thrombosis or Thrombotic Extension, in the Event of Acute Non-cirrhotic Portal Vein Thrombosis Secondary to a Local Cause. Completed NCT05360641
40 A Humanitarian Device Exemption Treatment Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma in Patients With Portal Vein Thrombosis Completed NCT01556282
41 Portal Vein Thrombosis Relevance On Liver Cirrhosis: Italian Venous Thrombotic Events Registry Completed NCT01470547
42 Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Treatment Combined With Propranolol for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis: A Randomized Controlled Trial Completed NCT01326949
43 Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms Completed NCT01816256
44 Proteomic Analysis of Human Hepatocellular Carcinoma Associated With Portal Vein Thrombosis Completed NCT01177631
45 Pair Production PET Imaging to Detect Particle Distribution in Patients Undergoing Yttrium-90 Radioembolization With Large Hepatocellular Carcinomas or Associated Portal Vein Thrombosis Completed NCT02848638
46 Neoadjuvant Transartery Chemoembolization Plus Artery Infusion Chemotherapy With Surgery Versus Surgery Alone for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: a Randomized Clinical Trial Recruiting NCT04181931
47 Follow-up and Survival of Cirrhotic and Non Cirrhotic Patients With Portal Vein Thrombosis Treated With Transjugular Intrahepatic Portosystemic Shunt Recruiting NCT03031717
48 Vienna Vascular Liver Disease Study: Characterization of Patients With Vascular Liver Disease - a Registry With Biobank Recruiting NCT03541057
49 Prospective Evaluation of Coagulation Status and Thromboelastometry Guided Management of Genetic and Acquired Thrombophilia in Patients With Portal Vein Thrombosis and Budd-Chiari Syndrome Recruiting NCT05123326
50 Efficacy and Safety of Dabigatran in Patients With Cirrhosis and Portal Vein Thrombosis-A Randomized Placebo Controlled Trial Recruiting NCT04433481 Dabigatran

Search NIH Clinical Center for Portal Vein Thrombosis

Genetic Tests for Portal Vein Thrombosis

Genetic tests related to Portal Vein Thrombosis:

# Genetic test Affiliating Genes
1 Portal Vein Thrombosis 28

Anatomical Context for Portal Vein Thrombosis

Organs/tissues related to Portal Vein Thrombosis:

MalaCards : Liver, Neutrophil, Endothelial, Spleen, Myeloid, Pancreatic Islet, Pancreas

Publications for Portal Vein Thrombosis

Articles related to Portal Vein Thrombosis:

(show top 50) (show all 5788)
# Title Authors PMID Year
1
Portal vein thrombosis treated using danaparoid sodium and antithrombin III. 53 62
20422871 2010
2
Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism. 53 62
19864937 2010
3
Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study. 53 62
20305756 2009
4
Resolution of preoperative portal vein thrombosis after administration of antithrombin III in living donor liver transplantation: case report. 53 62
19917415 2009
5
Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. 53 62
19067476 2009
6
Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. 53 62
18331238 2009
7
Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology. 53 62
19024130 2008
8
Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study. 53 62
18699979 2008
9
Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings. 53 62
18023093 2007
10
High FVIII level is associated with idiopathic portal vein thrombosis in South India. 53 62
17524760 2007
11
A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization. 53 62
17416468 2007
12
Idiopathic portal vein thrombosis and FVIII levels. 53 62
17011614 2007
13
Factor V Leiden and prothrombin gene G20210A mutations are uncommon in portal vein thrombosis in India. 53 62
17090840 2006
14
[Modified CLIP score as a new prognostic index for patients with hepatocellular carcinoma]. 53 62
16804346 2006
15
Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. 53 62
16773687 2006
16
Factor V Leiden is not commonly associated with idiopathic portal vein thrombosis in southern India. 53 62
16877827 2006
17
[Survival analysis for patients with hepatocellular carcinoma according to stage, liver function and treatment modalities]. 53 62
16565605 2006
18
Increased plasma prothrombin concentration in cirrhotic patients with portal vein thrombosis and prothrombin G20210A mutation. 53 62
16493481 2006
19
Mesenteric and portal vein thrombosis associated with hyperhomocysteinemia and heterozygosity for factor V Leiden mutation. 53 62
16437705 2005
20
Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. 53 62
15947552 2005
21
Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. 53 62
15710992 2005
22
Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study. 53 62
15309526 2004
23
Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. 53 62
15466827 2004
24
Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma. 53 62
15209629 2004
25
Portal vein thrombosis complicating islet transplantation in a recipient with the Factor V Leiden mutation. 53 62
15257060 2004
26
Inherited prothrombotic defects in Budd-Chiari syndrome and portal vein thrombosis: a study from North India. 53 62
15198356 2004
27
Pathologic analysis of right-lobe graft failure in adult-to-adult live donor liver transplantation. 53 62
14615823 2003
28
[Portal vein thrombosis associated with factor V Leiden mutation in a woman who underwent exchange transfusion at birth]. 53 62
12910230 2003
29
[Thrombophilic disorders in children and adolescents with portal vein thrombosis]. 53 62
14502338 2003
30
Detection of circulating hepatocellular carcinoma cells in peripheral venous blood by reverse transcription-polymerase chain reaction. 53 62
14607627 2002
31
Plasma thrombopoietin in patients with cavernous transformation of the portal vein. 53 62
11843299 2002
32
[Relation between transcatheter arterial chemoembolization and time of death in patients with hepatic carcinoma]. 53 62
11859720 2001
33
Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India. 53 62
11584361 2001
34
Hepatocellular carcinoma in Central Europe: prognostic features and survival. 53 62
11115830 2001
35
Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. 53 62
11129271 2000
36
Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors - a multicentre case-control study. For the Childhood Thrombophilia Study Group. 53 62
11122096 2000
37
Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. 53 62
11001884 2000
38
Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. 53 62
10733537 2000
39
Deficiency of natural anticoagulant proteins C, S, and antithrombin in portal vein thrombosis: a secondary phenomenon? 53 62
10716684 2000
40
The role of natural anticoagulant deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis. 53 62
10636214 2000
41
Paraneoplastic syndromes in patients with hepatocellular carcinoma in Taiwan. 53 62
10463978 1999
42
[Resistance to activated protein C and portal vein thrombosis: two new cases and review of the literature]. 53 62
10434351 1999
43
Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. 53 62
9869612 1999
44
Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection--a single-center analysis including 132 patients. 53 62
9842968 1998
45
[The detection of circulating hepatocellular carcinoma cells in peripheral venous blood by reverse transcription-polymerase chain reaction and its clinical significance]. 53 62
11825477 1998
46
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. 53 62
9731568 1998
47
[Successful treatment of hepatocellular carcinoma with All-trans-retinoic acid]. 53 62
9569727 1998
48
Portal vein thrombosis in association with factor V Leiden mutation in a patient with hepatocellular carcinoma. 53 62
9212850 1997
49
Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. 53 62
9245936 1997
50
Factor V Leiden is not common in children with portal vein thrombosis. 53 62
9157577 1997

Variations for Portal Vein Thrombosis

Expression for Portal Vein Thrombosis

Search GEO for disease gene expression data for Portal Vein Thrombosis.

Pathways for Portal Vein Thrombosis

Pathways related to Portal Vein Thrombosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.53 VWF THPO THBD SERPINC1 PLG PF4
2
Show member pathways
12.5 THBD SERPINC1 F8 F5 F3 F2
3
Show member pathways
12.07 VWF THBD SERPINC1 PLG PF4 F8
4
Show member pathways
12 AFP ALB F2 F5 PLG SERPINC1
5 11.64 THPO MPL JAK2 CRP
6
Show member pathways
11.54 VWF THPO MPL F2
7
Show member pathways
11.24 F2 ALB AFP
8 11.15 PF4 F3 F2
9 10.3 PLG F2

GO Terms for Portal Vein Thrombosis

Cellular components related to Portal Vein Thrombosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.25 AFP ALB APOH CD40LG CRP F2
2 endoplasmic reticulum lumen GO:0005788 10.1 SERPINC1 F8 F5 F2 ALB AFP
3 collagen-containing extracellular matrix GO:0062023 10.1 APOH F2 F3 PF4 PLG SERPINC1
4 blood microparticle GO:0072562 9.97 SERPINC1 PLG F2 ALB
5 extracellular space GO:0005615 9.81 AFP ALB APOH CD40LG CRP F2
6 platelet alpha granule lumen GO:0031093 9.73 VWF PLG PF4 F8 F5 ALB

Biological processes related to Portal Vein Thrombosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet activation GO:0030168 9.97 VWF PF4 F2 CD40LG
2 acute-phase response GO:0006953 9.88 F8 F2 CRP
3 blood coagulation GO:0007596 9.86 VWF THBD SERPINC1 PLG F8 F5
4 negative regulation of fibrinolysis GO:0051918 9.76 APOH F2 PLG THBD
5 thrombopoietin-mediated signaling pathway GO:0038163 9.73 THPO MPL
6 regulation of blood coagulation GO:0030193 9.62 SERPINC1 F2 APOH
7 regulation of body fluid levels GO:0050878 9.43 F8 F5 F2
8 hemostasis GO:0007599 9.28 VWF THBD SERPINC1 PLG F8 F5

Sources for Portal Vein Thrombosis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....